Amphotericin B-conjugated biogenic silver nanoparticles as an innovative strategy for fungal infections

Ahmad, Aftab; Wei, Yun; Syed, Fatima; Tahir, Kamran; Taj, Raheela; Khan, Arif Ullah; Hameed, Muhammad Usman; Yuan, Qipeng

doi:10.1016/j.micpath.2016.08.031

Cited by 65 publications

(46 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reaction mixture from different synthesis batch (inset image in Figure 1) shows various color intensity (yellowish to a brownish colour) suggesting the production variation in the citrate reduction method. However, the obtained SPR peaks of the AgNPs samples (A -E) lies around 416 to 441 nm, within the accepted range as in Ahmad et al (2016). It appears that AgNP with a strong and sharp extinction peak can be observed at 380-420 nm in an optical experiment.…”

Section: Size and Morphology Of Agnpssupporting

confidence: 72%

Evaluation of anti bacteria effects of citrate-reduced silver nanoparticles in Staphylococcus aureus and Escherichia coli

Hor¹,

Awang²,

Dyana³

et al. 2019

ijrps

View full text Add to dashboard Cite

Silver nanoparticles (AgNPs) has long known for its inhibitory and bactericidal effects. However, due to its’ attractive antibacterial property, on-going research with various synthesis strategies actively been conducted. In this study, the synthesis of AgNPs was reported, using a simple chemical reduction method with citrate as the reducing agent TEM was used to characterize the obtained AgNPs. Then, Staphylococcus aureus and Escherichia coli were used to identify the antibacterial activity of AgNPs. The inhibition effects of AgNPs against these two bacteria were observed via disc diffusion, and MIC assays and the effects of AgNPs mode of action on both bacteria were further observed under TEM. The formation of AgNPs at ̴ 400 nm, which is the surface plasmon resonance peak was observed using Uv-Vis spectroscopy. The size of AgNPs mostly in the range of 1-10 nm and their morphology appeared to be spherical. Based on the MIC assay, Escherichia coli exhibit low MIC value with 0.049 mg/ml as compared to Staphylococcus aureus with0.391 mg/ml MIC value; correspond to the effective antibacterial activity by the citrate-reduced AgNPs. Further observation on the bacterial surface structure can be seen with cross-sectional TEM image, and it provides an insight into the AgNPs mechanistic aspects of AgNPs against Staphylococcus aureus and Escherichia coli. Silver nanoparticles have been successfully synthesised using the citrate reduction method. Results obtained in this study thus elucidating promising findings to employed AgNPs as an antibacterial agent, and this composition needs to be further study and develop into an antibacterial agent.

show abstract

Section: Size and Morphology Of Agnpssupporting

confidence: 72%

Evaluation of anti bacteria effects of citrate-reduced silver nanoparticles in Staphylococcus aureus and Escherichia coli

Hor¹,

Awang²,

Dyana³

et al. 2019

ijrps

View full text Add to dashboard Cite

show abstract

“…C. albicans and C. tropicalis. 223 Apart from such drug delivery example, green synthesized AgNPs are also reported to exhibits antifungal activity due to its bio-coating in combination with its size. Ishida et al, reported antifungal activity green synthesized AgNPs from the fungus Fusarium oxysporum.…”

Section: Green Synthesized Silver Nanoparticles Controlling Antifungamentioning

confidence: 99%

Green synthesis of silver nanoparticles: biomolecule-nanoparticle organizations targeting antimicrobial activity

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Ahmad et al (2016) produced a conjugate system with AmB and metal nanoparticles that displayed synergistic antifungal activity due to the antimicrobial property of silver against C. albicans and C. tropicalis . Niemirowicz et al (2016) reported synergistic activity for the combination of polyenes and magnetic nanoparticles.…”

Section: New Antifungal Formulations and New Antifungal Drug Structurmentioning

confidence: 99%

Antifungal Therapy: New Advances in the Understanding and Treatment of Mycosis

et al. 2017

View full text Add to dashboard Cite

The high rates of morbidity and mortality caused by fungal infections are associated with the current limited antifungal arsenal and the high toxicity of the compounds. Additionally, identifying novel drug targets is challenging because there are many similarities between fungal and human cells. The most common antifungal targets include fungal RNA synthesis and cell wall and membrane components, though new antifungal targets are being investigated. Nonetheless, fungi have developed resistance mechanisms, such as overexpression of eﬄux pump proteins and biofilm formation, emphasizing the importance of understanding these mechanisms. To address these problems, different approaches to preventing and treating fungal diseases are described in this review, with a focus on the resistance mechanisms of fungi, with the goal of developing efficient strategies to overcoming and preventing resistance as well as new advances in antifungal therapy. Due to the limited antifungal arsenal, researchers have sought to improve treatment via different approaches, and the synergistic effect obtained by the combination of antifungals contributes to reducing toxicity and could be an alternative for treatment. Another important issue is the development of new formulations for antifungal agents, and interest in nanoparticles as new types of carriers of antifungal drugs has increased. In addition, modifications to the chemical structures of traditional antifungals have improved their activity and pharmacokinetic parameters. Moreover, a different approach to preventing and treating fungal diseases is immunotherapy, which involves different mechanisms, such as vaccines, activation of the immune response and inducing the production of host antimicrobial molecules. Finally, the use of a mini-host has been encouraging for in vivo testing because these animal models demonstrate a good correlation with the mammalian model; they also increase the speediness of as well as facilitate the preliminary testing of new antifungal agents. In general, many years are required from discovery of a new antifungal to clinical use. However, the development of new antifungal strategies will reduce the therapeutic time and/or increase the quality of life of patients.

show abstract

Amphotericin B-conjugated biogenic silver nanoparticles as an innovative strategy for fungal infections

Cited by 65 publications

References 51 publications

Evaluation of anti bacteria effects of citrate-reduced silver nanoparticles in Staphylococcus aureus and Escherichia coli

Evaluation of anti bacteria effects of citrate-reduced silver nanoparticles in Staphylococcus aureus and Escherichia coli

Green synthesis of silver nanoparticles: biomolecule-nanoparticle organizations targeting antimicrobial activity

Antifungal Therapy: New Advances in the Understanding and Treatment of Mycosis

Contact Info

Product

Resources

About